Inovio misses Q3 revenues; CSL rebrands its flu vaccines business;

> Inovio ($INO) missed a Q3 consensus revenue estimate of $29 million from Zack's, instead bringing in $24.2 million. Earnings report

> CSL announced that its flu vaccines business will operate under the brand Seqirus. Release

> France-based Valneva's U.S. subsidiary, Intercell USA, has entered into a distribution and marketing services agreement with VaxServe, a Sanofi Pasteur company, for Valneva's Japanese encephalitis vaccine. Release

> Researchers at Washington University in St. Louis have identified broadly neutralizing antibodies that protect against infection from a range of alphaviruses, including Chikungunya virus. Release

> Caladrius Biosciences ($CLBS) presented additional data at the Society for Immunotherapy of Cancer Annual Meeting supporting its lead candidate for the treatment of metastatic melanoma. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.